Dr. Payam Mohassel

Nicholas Maragakis treats patients with motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). This care is coordinated with the Johns Hopkins Center for ALS Specialty Care, a multidisciplinary clinic with expertise in treating patients with ALS and providing support to their caregivers. He serves as medical director of the ALS Clinical Trials Unit, an extension of the multidisciplinary clinic that seeks to facilitate opportunities for patients with ALS to participate in clinical trials that could advance the treatment of this disease. Dr. Maragakis is interested in the basic science of understanding neurodegenerative diseases, as well as the translational potential of therapeutic compounds developed in the laboratory. His fundamental research interest is in using stem cells — more specifically, stem cell-derived motor neurons and glia — for understanding the development and propagation of ALS. His laboratory has been involved in creating and characterizing lines of stem cells from patients with ALS using induced pluripotent stem cell (iPSC) methodologies. The laboratory has a large library of iPSCs from patients with familial ALS and from patients with sporadic ALS. The utilization of this library of iPSCs has facilitated the development of a spinal cord-specific iPSC-astrocyte/motor neuron co-culture system, which has been leveraged for the development of assays that can be used for both the basic understanding of ALS astrocyte and motor neuron biology as well as, eventually, drug screening for ALS therapeutics. His laboratory has taken its long-standing interests in astrocyte biology, as it relates to ALS, to develop a program that investigates astrocyte-specific mechanisms as contributors to the progression (both temporally and anatomically) of disease in ALS. In this vein, there is an interest in astrocytic glutamate transporters and, more recently, astrocyte hemichannels and gap junctions. Dr. Maragakis is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, 15q11.2 Microdeletion, and Spinal Muscular Atrophy (SMA).

Dr. Brett Morrison specializes in neuromuscular disorders in adults including peripheral neuropathies, amyotrophic lateral sclerosis, myasthenia gravis and muscle diseases. Dr. Morrison is currently the site principal investigator for clinical trials investigating new treatments for chronic inflammatory demyelinating polyneuropathy (CIDP) and painful diabetic peripheral neuropathy. Dr. Morrison's research interests include investigations into the mechanisms of nerve regeneration and common peripheral neuropathies. Current research focuses on better understanding the role of the immune system in peripheral nerves and targeting these pathways for the development of new treatments. Dr. Brett Morrison received his M.D. and Ph.D. from Mount Sinai Medical School in New York City. He completed his medical internship at the University of Maryland and residency in neurology at The Johns Hopkins Hospital. He then completed a fellowship in Clinical Neurophysiology at The Johns Hopkins Hospital. Dr. Morrison is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, and Spinal Muscular Atrophy (SMA).

Dr. Jeffrey Rothstein focuses on neuromuscular diseases, with a particular focus on Amyotrophic lateral sclerosis (ALS). Other clinical areas relevant to his laboratory-based research include idiopathic stupor, epilepsy, and motor neuron degeneration. His laboratory includes more than 25 post-doctoral fellows, neurology residents, neuromuscular fellows, junior faculty, undergraduate students, technicians, and ALS clinic staff. He has been the principal and/or local investigator in more than 20 national or international trials in ALS. He is the author of more than 360 articles on basic and clinical neuroscience. Dr. Rothstein's laboratory research is funded through the National Institutes of Health, the Dept of Defense, Target ALS, Maryland TEDCO, Alzheimer's Drug Discovery Foundation, the Muscular Dystrophy Association, the ALS Association, and Answer ALS. Dr. Jeffrey Rothstein received a masters degree in neurochemistry from the University of Chicago and a Ph.D. in physiology and biophysics from the University of Illinois Health Sciences Center. He then obtained his medical degree from the University of Illinois College of Medicine. He went on to complete an internship at the University of North Carolina Memorial Hospital before joining The Johns Hopkins for his residency. While at Johns Hopkins, he became chief resident in neurology and completed his fellowship in neuromuscular disease. He has been Professor of Neurology and Neuroscience at Johns Hopkins for more than 25 years. Dr. Rothstein is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Spinal Muscular Atrophy Type 3.